We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Seegene

Seegene, Inc. is a developer of multiplex molecular technologies and multiplex clinical molecular diagnostics for inf... read more Featured Products: More products

Download Mobile App




RT-PCR Test Detects Monkeypox Virus Delivers Results in 90 Minutes

By LabMedica International staff writers
Posted on 29 Jun 2022

Monkeypox is an acute zoonotic infection disease caused by the monkeypox virus (MPXV). More...

The disease is mainly transmitted by animals, but it can also be transmitted from person to person through physical contact, body fluids, or even contaminated objects, showing symptoms such as fever, severe headache, and muscle pain. As with many infectious diseases, accurate diagnosis is crucial as treatments are more effective in the early stages of infection. PCR test is known as the gold standard to accurately detect MPXV, so it can be used effectively to prevent the rapid spread of the virus. Timely PCR testing vital, especially for individuals with a suspected case, as the incubation period for the monkeypox infection ranges between five to 21 days. Now, a new real-time PCR assay accurately detects MPXV specifically with a single test and delivers results within 90 minutes.

Seegene, Inc. (Seoul, Korea) has developed a PCR test to detect the MPXV. The Novaplex MPXV Assay, which specifically targets the MPXV, was swiftly developed using the company's AI-based automated test development system, known as SGDDS (Seegene Digitalized Development System), and technologies refined over 20 years of MDx expertise.

According to the World Health Organization, the MPXV is an "evolving health threat that requires collective attention and coordinated action," calling on member states to step up surveillance, contact tracing and testing. The MPXV has been detected in over 50 nations, with South Korea confirming its first case last week. The strain currently circulating in the Northern Hemisphere has an estimated fatality rate of between 3-6% and is considered especially dangerous for children and those with weak immune systems.

Seegene’s Novaplex MPXV Assay can identify positive cases of the MPXV in 90 minutes. The company swiftly developed the product to help curb the worldwide spread. Seegene plans to provide the assay to countries that have detected the virus.

"The monkeypox virus outbreak shows that endemic viruses can rapidly spread to the rest of the world and it's a warning that new pandemics can emerge and threaten our lives at any time," said Dr. Jong-Yoon Chun, CEO of Seegene. "We will continue our efforts to develop products that can accurately diagnose any virus to help prevent new infectious diseases from taking hold and becoming a pandemic."

Related Links:
Seegene, Inc. 


Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
COVID-19 Antigen Self-Test
Panbio COVID-19 Antigen Self-Test
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.